Core Insights - Gain Therapeutics, Inc. is advancing its lead drug candidate GT-02287 for Parkinson's disease, with presentations scheduled at Neuroscience 2024 showcasing preclinical data [1][5] Group 1: Drug Candidate Information - GT-02287 is an allosteric protein modulator that targets the lysosomal enzyme glucocerebrosidase (GCase), which is affected by GBA1 mutations, a common genetic factor in Parkinson's disease [4] - Preclinical studies indicate that GT-02287 restores GCase function, reduces neuroinflammation, and improves motor and cognitive functions in Parkinson's disease models [4][5] - The drug has shown potential to slow disease progression, with significant improvements in cognitive and motor performance in mouse models [5] Group 2: Presentation Details - Two late-breaking poster presentations will occur on October 6, 2024, focusing on GT-02287's effects on Tau accumulation and mitochondrial function in Parkinson's disease models [2][3] - The presentations will be part of the Society for Neuroscience's annual event, highlighting the significance of the findings [1] Group 3: Funding and Support - Gain Therapeutics has received funding from The Michael J. Fox Foundation and The Silverstein Foundation, as well as support from the Eurostars-2 program and the European Union Horizon 2020 research initiative [6] Group 4: Company Overview - Gain Therapeutics is a clinical-stage biotechnology company specializing in the discovery of next-generation allosteric therapies, with GT-02287 currently in Phase 1 clinical trials [7] - The company utilizes an advanced drug discovery platform, Magellan™, which employs AI and machine learning to identify novel allosteric binding sites for drug development [8][9]

Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson's Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024 BETHESDA, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the Phase 1 study conducted to e ...

Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation of Phase 1b Study of GT-02287 in Parkinson's Disease Patients Anticipated in Q4 2024 BETHESDA, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today report ...

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the last healthy subject in the multiple ascending dose (MAD) part of its Phase 1 study has completed the highest planned dose levels. No discontinuations or ...

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson's Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the last healthy sub ...

Investors might want to bet on Gain Therapeutics, Inc. (GANX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analys ...

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open. Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-po ...

Core Viewpoint - Gain Therapeutics, Inc. is advancing the discovery and development of next-generation allosteric small molecule therapies, with a focus on treating neurodegenerative diseases, rare genetic disorders, and oncology [3][5]. Company Update - The interim-CEO and current CFO Gene Mack will host a business and corporate update call on July 1, 2024, at 8:30 am ET [1]. - Participants can access the call through the company's website, and a recorded version will be available within 24 hours after the event [2]. Drug Discovery Platform - Gain Therapeutics utilizes its Magellan™ drug discovery platform, which employs AI-supported structural biology and supercomputer-powered models to identify novel allosteric binding sites on proteins [6]. - The platform can explore vast chemical spaces of over five trillion compounds to find suitable small molecule hits for experimental validation [6]. Lead Drug Candidate - Gain's lead drug candidate, GT-02287, is currently being evaluated in a Phase 1 clinical trial for the treatment of Parkinson's disease [5].

Mr. Mack is the Company's Current CFO "On behalf of Gain, I would like to thank Matthias for his significant contribution to the development of our company, as we advanced our lead candidate, GT-02287, into clinical development. Matthias played an instrumental role building the preclinical dossier for GT-02287 including the most recent positive data presented this week at FENS Forum 2024, in which administration of GT-02287 was associated with significant improvement in cognitive performance and other relat ...

Core Points - Gain Therapeutics, Inc. has appointed Gene Mack as interim CEO following the departure of Matthias Alder, while Khalid Islam will serve as Executive Chairman until a permanent CEO is found [2] - The company’s lead drug candidate, GT-02287, is in clinical development for Parkinson's disease and has shown significant improvements in cognitive performance in preclinical models [3][4] - GT-02287 functions as an allosteric protein modulator, restoring the function of the glucocerebrosidase enzyme, which is impaired due to GBA1 gene mutations [4] - The drug has demonstrated the ability to reduce neuroinflammation, neuronal death, and increase dopamine levels, alongside lowering plasma neurofilament light chain levels, a biomarker for neurodegeneration [4] - Gain Therapeutics has received funding support for its Parkinson's disease program from notable organizations including The Michael J. Fox Foundation and the Eurostars-2 joint program [5] - The company utilizes an advanced drug discovery platform, Magellan™, which leverages AI and supercomputing to identify novel allosteric binding sites on proteins [7][8] Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric therapies [6] - The company’s lead candidate, GT-02287, is currently undergoing a Phase 1 clinical trial [6]